How pharma reps impact physician prescribing
A new study led by The University of California researchers and published in JAMA reveals surprising findings.
View ArticleTop 5 specialty drug management issues
The 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.
View ArticleCombination pack approved for breast cancer treatment
FDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.
View ArticleDrugmaker recalls samples of antiplatelet drug
AstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
View ArticleInvestigational drug appears beneficial in preventing migraines
Lilly's galcanezumab successful in three phase 3 migraine studies. Here are the findings.
View ArticleFirst generic Strattera for ADHD approved
FDA has approved the first generic versions of Strattera (atomoxetine) for the treatment of attention deficit/hyperactivity disorder.
View ArticleAsthma biologic may reduce oral steroid use
A new trial for AstraZeneca’s benralizumab shows surprising results for severe asthma patients.
View ArticleFDA gives once-daily HIV therapy go-ahead
FDA approves Isentress at a higher dose for HIV-1 infected patients.
View ArticleFDA approves first generic Truvada for HIV
The first generic Truvada for treating and preventing HIV will be available, but when?
View ArticleFDA approves EpiPen rival
Adamis’ epinephrine injection promises to be a lower-cost alterative to EpiPen.
View ArticleFDA to drug maker: Pull opioid pain drug
Potential public health consquences prompts FDA to request removal of opioid pain medication.
View ArticleEvolving hepatitis C pipeline offers hope to patients
Cost burden prompts payers to consider appropriate utilization
View ArticleFDA approves Bayer’s Bluetooth-enabled auto-injector for multiple sclerosis
FDA has approved a supplemental Biologics License Application (sBLA) for Bayer’s myBETAapp and BETACONNECT Navigator for multiple sclerosis (MS) patients
View ArticleNew antibiotic approved for acute bacterial skin infections
FDA approved the use of a new fluoroquinolone antibiotic to treat ABSSI.
View ArticleNew universal companion diagnostic paves the way for precision oncology
FDA approves new diagnostic test for non-small cell lung cancer.
View ArticlePopular insulin meets target in real-world study
Novo Nordisk’s DEVOTE study reveals interesting findings.
View ArticleBrace for a barrage of biosimilars
The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
View ArticleOral specialty drug options on the horizon
As more specialty drugs are approved, cost control strategies are key.
View ArticleOncology treatments: Three areas to watch
While targeted cancer therapies make up a big part of the pipeline, there are three areas that oncology experts want you to keep on your radar.
View ArticleGroundbreaking gene therapies in store for hemophilia
Treatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
View Article
More Pages to Explore .....